Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.-10. (Canceled)

11. (Previously presented) An apoptotic composition that induces apoptosis by binding to a Bcl-2 family member protein and preferentially inducing apoptosis in a cell that over-expresses the Bcl-2 family member protein, the composition having the following formula II,



(II)

having an absolute configuration of [2R, 3R, 4S, 7S, 8R], and wherein

R_1 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_2 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_3 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_4 is hydrogen, a C_1-C_8 linear or branched alkane, a C_1-C_8 hydroxyalkane, or a substituted alkyl group;

R_5 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_3-C_8 di- or tri-alkylamine, a C_1-C_8 carboxylic acid, a C_2-C_8 amide, or a substituted alkyl group; and

R_6 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group.

12. (Previously presented) The composition of claim 11, further comprising a pharmaceutically acceptable carrier.

13. (Previously presented) The composition of claim 11 for use in treating an apoptosis-associated disease in a subject in need thereof.

14. (Canceled)

15. - 20. (Canceled)

21. (Previously presented) A method for treating a subject having an apoptosis-associated disease, comprising administering to the subject a therapeutically effective amount of a composition, wherein the composition comprises an antimycin of the following formula, and having an absolute configuration of [2R, 3R, 4S, 7S, 8R]:



(II)

wherein R_1 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_2 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_3 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_4 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 carboxylic acid, or a substituted alkyl group;

R_5 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-alkylamine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group; and

R_6 is hydrogen, a C_1-C_8 linear or branched alkane, hydroxyl, a C_1-C_8 hydroxyalkane, amino, a C_1-C_8 di- or tri-amine, a C_1-C_8 amide, a C_1-C_8 carboxylic acid, or a substituted alkyl group.

22. (Original) The method of claim 21, wherein the antimycin derivative is 2-methoxy ether antimycin A or A_3.

23. (Canceled)

24. (Previously presented) The method of claim 21, wherein the subject is human.

25. (Previously presented) The method of claim 21, further comprising administering a pharmaceutical carrier.

26. (Previously presented) The method of claim 21, wherein the administration is intravenous, subcutaneous, intramuscular, intradermal, transdermal, intrathecal, intracerebral, intraperitoneal, epidural or oral.